Papiernik named chairman at Sofinnova Partners; Cara shares surge on positive data for uremic pruritus
→ Twenty years after joining Sofinnova Partners in Paris, Antoine Papiernik is taking the chairman’s post. Papiernik is well known in VC circles on both sides of the Atlantic, and played a leading role investing on a long list of biotechs like Actelion and ProQR. Papiernik succeeds Denis Lucquin who remains a Managing Partner.
→ Shares of Cara Therapeutics $CARA shot up 15% this morning after the Stamford, CT based biotech reported positive top-line results demonstrating from Part A of its Phase II/III trial showing that I.V. CR845 met both primary and secondary endpoints for efficacy (reduced itching and improved quality of life, respectively) in patients with uremic pruritus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.